Tiroit kanseri genetiği

Year 2013, Volume: 30 Issue: 1s, 55 - 62, 28.11.2013

Sengul Tural , Akın Tekcan , Mehmet Elbistan Nurten Kara

Abstract

iroit kanseri son yıllarda sıklığı giderek artış gösteren malignensilerden biridir. Moleküler mekanizmasının anlaşılmasındaki ilerlemeler, hastalığın önlenmesi, erken tanısı ve tedavisinde yarar sağlamaktadır. Somatik mutasyonlar ve diğer moleküler değişiklikler, tiroit kanseri tanısı için yararlı prognostik belirteçler olarak kabul edilmiş ve klinik uygulamaya da girmeye başlamıştır. Bu derlemede tiroit kanserinin genetik temeli anlatılmıştır. Tiroit kanserinde yaygın bulunan BRAF ve RAS gen mutasyonlarının yanı sıra RET/PTC ve PAX8/PPARγ kromozomal yeniden düzenlenmeleri de açıklanmıştır. Ayrıca gen ekspresyon profili, microRNA, epigenetik, genom çaplı ilişki çalışmaları, tek nükleotid polimorfizmi (SNP) analizleri ve tiroit karsinogenezinde ilişkili diğer genler açıklanmıştır.

Keywords

Gen mutasyonu, Kromozomal yeniden düzenlenmeler, Somatik mutasyon, Tiroit kanseri

References

• Arighi, E., Borello, M.G., Sariola, H., 2005. RET thyrosine kinase signalling in development andcancer. Cytokine Growth F.R. 16, 441-467.
• Begum, S., Rosenbaum, E., Henrique, R., Cohen, Y., Sidransky, D., Westra, W. H., 2004. BRAF mutations in a anaplastic thyroid carcinoma: Implications for tumor origin, diagnosis and treatment. Modern. Pathol. 17, 1359-1363.
• Bondeson, L., Bengtsson, A., Bondeson, A. G., Dahlenfors, R., Grimelius, L., Wedell, B., Mark, J., 1989. Chromosome studies in thyroidneo- plasia. Cancer. 64, 680-685.
• Bonora, E., Evangelisti, C., Bonichon, F., Tallini, G., Romeo, G., 2006. Novel germline variants identified in the iner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. Brit. J. Cancer. 95, 1529-1536.
• Büttel, I., Fechter, A.&Schwab, M., 2004. Common fragile sites and cancer: targeted cloning by insertional mutagenesis. Ann. NY Acad. Sci. 1028, 14-27.
• Cantara, S., Capezzone, M., Marchisotta, S., Capuano, S., Busonero, G., Toti, Paolo., Di Santo, A., Caruso, G., Carli, A.F., Brilli, L., Montanaro, A., Pacini, F., 2010. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J. Clin. Endocr. Metab. 95, 1365-1369.
• Cassol, C.A., Asa, S.L., 2010. Molecular pathology of thyroid cancer. Diagnostic histopathology. 17, 124-139.
• Caudill, C.M., Zhu, Z., Ciampi, R., Stringer, J.R. & Nikiforov, Y. E., 2005. Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: A model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J. Clin. Endocr. Metab. 90, 2364-2369.
• Chen, Y.T., Kitabayashi, N., Zhou, X.K., Fahey, T.J. 3rd & Scognamiglio, T., 2008. MicroRNA analysis as a potential diagnostic tool for papil- lary thyroid carcinoma. Modern. Pathol. 21, 1139-1146.
• Chiappetta, G., Ferraro, A., Vuttariello, E., Monaco, M., Galdiero, F., De Simone, V., Califano, D., Pallante, P., Botti, G., Pezzullo, L., Pierantoni, G.M., Santoro, M., Fusco, A., 2008. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur. J. Cancer. 44, 1015-1021.
• Ciampi, R., Knauf, J.A., Kerler, R., Gandhi, M., Zhu, Z., Nikiforova, M.N., Rabes, H.M., Fagin, J.A., Nikiforov, Y.E., 2005. Oncogenic AKAP9- BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest. 115, 94-101.
• Ciampi, R., Nikiforov, Y.E., 2005. Alterations of the BRAF gene in thyroid tumors. Endocr. Pathol. 16, 163-72.
• Corvi, R., Berger, N., Balczon, R., Romeo, G., 2000. RET/PCM-1: A novel fusion gene in papillary thyroid carcinoma. Oncogene. 19, 4236-4242
• Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N. et al. 2002. Mutations of the BRAF gene in human cancer. Nature. 417, 949-954.
• Esapa, C.T., Johnson, S.J., Kendall-Taylor, P., Lennard, T.W., Harris, P.E., 1999. Prevalance of Ras mutations in thyroid neoplasia. Clin. Endo- crinol. (Oxf). 50, 529-535.
• Fagin, J.A., 2002. Minireview: Branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol. Endo- crinol. 16, 903-911.
• French, C.A., Alexander, E.K., Cibas, E.S., Nose, V., Laguette, J., Faquin, W., Garber, J., Moore, F. Jr., Fletcher, J.A., Larsen, P.R., Kroll, T.G., 2003. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am. J. Pathol. 192, 1053-1060.
• Garcia-Rostan, G., Costa, A.M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M.J., Herrero, A., Fusco, A., Cameselle-Teijeiro, J., Santoro, M., 2005. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer. Res. 65, 10199-10207.
• Guerra, A., Sapio, M. R., Marotta, V., Campanile, E., Moretti, M. I., Deandrea, M., Motta, M., Limone, P.P., Fenzi, G., Rossi, G., Vitale, M., 2011. Prevalance of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr. J. 58, 31-38.
• Hamatani, K., Eguchi, H., Ito, R., Mukai, M., Takahashi, K., Taga, M., Imai, K., Cologne, J., Soda, M., Arihiro, K., Fujihara, M., Abe, K., Hayashi, T., Nakashima, M., Sekine, I., Yasui, W., Hayashi, Y., Nakachi, K. 2008. RET/PTC rearrangements preferentially occurred in papil- lary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer. Res. 68, 7176-7182.
• Hassell, L.A., Gillies, E.M., Dunn, S.T., 2012. Cytologic and molecular diagnosis of thyroid cancers. Cancer. Cytopathol. 120, 7-17.
• Ho, Y.S., Wang, Y.J., Lin, J.K.1996. Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Mol Carcinog. 16, 20-31.
• Hou, P., Liu, D., Xing, M., 2007. Functional characterization of the T1799-1801del and A1799-816ins BRAF mutations in papillary thyroid cancer. Cell Cycle. 6, 377-379.
• Ito, T., Seyama, T., Mizuno, T., Tsuyama, N., Hayashi, T., Hayashi, Y., Dohi, K., Nakamura, N., Akiyama, M., 1992. Unique association of p53 mutations with undifferantiated but not with differentiated carcinomas of the thyroid gland. Cancer. Res. 52, 1369-1371.
• Jazdzewski, K., Boguslawska, J., Jendrzejewski, J., Liyanarachchi, S., Pachucki, J., Wardyn, K.A., Nauman, A., de la Chapelle, A., 2011. Thy- roid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J. Clin. Endocr. Metab. 96, 546-553.
• Kim, S.K., Hwank, S.T., Yoo, B.Y., Han, S.H., Kim, L.D., Song, K.H., Lim, S.D., Kim, W.S., Paik, N.S., 2011. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J. Clin. Endocr. Metab. 96, 658-664.
• Kimura, E.T., Nikiforova, M.N., Zhu, Z., Knauf, J.A., Nikiforov, Y.E., Fagin, J.A., 2003. High prevalance of BRAF mutations inthyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signalling pathwy in papillary thyroid carcinoma. Cancer. Res. 63, 1454-1457.
• Knauf, J.A., Sartor, M.A., Medvedovic, M., Lundsmith, E., Ryder, M., Salzano, M., Nikiforov, Y. E.Giordano, T. J., Ghossein, R. A., Fagin, J. A., 2011. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene. 30, 3153-3162.
• Kroll, T.G., Sarraf, P., Pecciarini, L., Chen, C.J., Mueller, E., Spiegelman, B.M., Fletcher, J.A., 2000. PAX8-PPAR gamma1 fusion oncogene in human thyroid carcinoma (corrected). Science. 289, 1357-1360.
• Lappinga, P.J., Kip N.S., Jin, L., Lloyd, R.V., Henry, M.R., Zhang, J., Nassar, A., 2010. HMGA2 gene expressionanalysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer. Cytopathol. 118, 287-297.
• Mathur, A., Weng, J.W., Moses, Steinberg, S.M., Rahbari, R., Kitano, M., Khanafshar, E., Ljung, B.M., Duh, Q.Y., Clark, O.H., Kebebew, E., 2010. A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery. 148, 1170-1176.
• Mazeh, H., Mizrahi, I., Halle, D., Ilyayev, N., Stojadinovic, A., Trink, B., Mitrani-Rosenbaum, S., Roistacher, M., Ariel, I., Eid, A., Freund, H. R., Nissan, A., 2011. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid. 21, 111-118.
• Minoletti, F., Butti, M. G., Coronelli, S., Miozzo, M., Sozzi, G., Pilotti, S., Tunnacliffe, A., Pierotti, M.A., Bongarzone, I., 1994. The two genes generating RET/PTC3 are localized in chromosomal band 10q11,2. Gene Chromosome. Canc. 11, 51-57.
• Miranda, C., Minoletti, F., Greco, A., Sozzi, G., Pierotti, M.A,. 1994. Refined localization of the human TPR gene to chromosome 1q25 by in situ hybridization. Genomics. 23, 714-715.
• Moses, W., Weng, J., Sansano, I., Peng M., Khanafshar, E., et al., 2010. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J. Surg. 34, 2589-2594.
• Musholt, T.J., Musholt, P.B., Khaladj, N., Schulz, D., Scheumann, G.F., Klempnauer, J., 2000. Prognostic significance of RET and NTRK1 rear- rangements in sporadic papillary thyroid carcinoma. Surgery. 128, 984-993.
• Nam, S.Y., Han, B.K., Ko, E.Y., Kang, S.S., Hahn, S.Y., Hwang, J.Y., Nam, M.Y., Kim, J.W., Chung, J.H., Oh, Y.L., Shin, J.H., 2010. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: A potential guide for selection of samples for molecular analysis. Thyroid. 20, 273-279.
• Nikiforov, Y. E., 2002. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 13, 3-16.
• Nikiforova, M.N., Caudill, C.M., Biddinger, P., Nikiforov, Y.E., 2002. Prevalence of RET/PTC rearrangements in Hashimoto’s thyroiditis and papillary thyroid carcinomas. Int. J. Surg. Pathol. 10, 15-22.
• Nikiforova, M.N., Ciampi, R., Salvatore, G., Santoro, M., Gandhi, M., Knauf, J.A., Thomas, G.A., Jeremiah, S., Bogdanova, T.I., Tronko, M.D., Fagin, J.A., Nikiforov, Y.E., 2004. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer. Lett. 209, 1-6.
• Nikiforov, Y. E., Nikiforova, M. N. 2011. Molecular genetics and diagnosis of thyroid cancer. Nat.Rev. Endocrinol. 7, 569-580.
• Nikiforova, M.N., Tseng, G.C., Steward, D., Diorio, D.&Nikiforov, Y.E., 2008. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocr. Metab. 93, 1600-1608.
• Nikiforova, M.N.&Nikiforov, Y. E., 2009. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 19, 1351-1361.
• Nikiforova, M.N., Chiosea, S.I.&Nikiforov, Y.E., 2009. MicroRNA expression profiles in thyroid tumors. Endocr. Pathol. 20, 85-91.
• Ohori, N.P., Nikiforova, M.N., Schoedel, K.E., LeBeau, S.O., et al., 2010. Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”. Cancer. Cytopathol. 118, 17-23.
• Pellegriti, G., De Vathaire, F., Scollo, C., Attard, M., 2009. Papillary thyroid cancer incidence in the volcanic area of Sicily. J. Natl. Cancer. Inst. 101, 1575-1583.
• Powell, D.J.Jr., Russell, J., Nibu, K., Li, G., Rhee, E., Liao, M., Goldstein, M., Keane, W.M., Santoro, M., Fusco, A., Rothstein, J.L. 1998. The RET/PTC3 oncogene: Metastatic solid-type papillary carcinomas in murine thyroids. Cancer. Res. 58, 5523-5528.
• Prasad, N.B., Somervell, H., Tufano, R.P.,Dackiw, A.P., Marohn, M.R., Califano, J.A., Wang, Y., Westra, W.H., Clark, D.P., Umbricht, C.B., Libutti, S.K., Zeiger, M.A. 2008. Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin. Cancer. Res. 14, 3327-3337.
• Russo, D., Damante, G., Puxeddu, E., Durante, C.& Filetti, S., 2011. Epigenetics of thyroid cancer and novel therapeutic targets. J. Mol. Endo- crinol. 46, R73-R81.
• Santoro, M., Dathan, N.A., Berlingieri, M.T., Bongarzone, I., Paulin, C., Grieco, M., Pierotti, M.A., Vecchio, G., Fusco, A., 1994. Molecular charcterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene. 9, 509-516.
• Takashi, M., Ritz, J., Cooper, G.M., 1985. Activation of a novel human transforming gene, ret, by DNA rearrengement. Cell. 42, 581-588.
• Trovisco, V., Vieira de Castro, I., Soares, P., Máximo, V., Silva, P., Magalhães, J., Abrosimov, A., Guiu, X. M., Sobrinho-Simões, M. 2004. BRAF mutations ars associated with some histological types of papillary thyroid carcinoma. J. Pathol. 202, 247-251.
• Visone, R., Russo, L., Pallante, P., De Martino, I., Ferraro, A., Leone, V., Borbone, E., Petrocca, F., Alder, H., Croce, C.M., Fusco, A., 2007. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 14, 791-798.
• Volante, M., Rapa, I., Gandhi, M., Bussolati, G., Giachino, D., Papotti, M., Nikiforov, Y.E., 2009. Ras mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J. Clin. Endocr. Metab. 94, 4735-4741.
• Xing, M., 2005. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer. 12, 245-262.
• Zhu, Z., Crampi, R., Nikiforova, M.N., Gandhi, M., Nikiforov, Y.E., 2006. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas:effets of the detection methods and genetic heterogeneity. J. Clin. Endocr. Metab. 91, 3603-3610.
• Zuo, H., Gandhi, J., Edreira, M.M., Hochbaum, D., Nimgaonkar, V.L., Zhang, P., Dipaola, J., Evdokimova, V., Altschuler, D.L., Nikiforov, Y.E., 2010. Downregulationof Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res. 70, 1389-1397.